Top

Published in:

Open Access 01-01-2018 | Original Article

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

Authors: Maarten O. Blanken, Geert W. Frederix, Elisabeth E. Nibbelke, Hendrik Koffijberg, Elisabeth A. M. Sanders, Maroeska M. Rovers, Louis Bont, on behalf of the Dutch RSV Neonatal Network

Published in: European Journal of Pediatrics | Issue 1/2018

Abstract

The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving.

Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.

Available only for authorised users

American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134(2):e620–e638. https://doi.org/10.1542/peds.2014-1666 CrossRef

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B (2013) Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 4:CD006602. https://doi.org/10.1002/14651858.CD006602.pub4

Anderson EJ, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B, Fullarton J, Rouffiac E, Vo P, Notario G, Campbell F, Paes B (2017) Burden of severe respiratory syncytial virus disease among 33-35 weeks’ gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr Infect Dis J 36(2):160–167. https://doi.org/10.1097/INF.0000000000001377 CrossRefPubMedPubMedCentral

Bindels PJE, Van de Griendt EJ, Grol MH, Van Hensbergen W, Steenkamer TA, Uijen JHJM, Burgers JS, Geijer RMM, Tuut M. Dutch general practitioner society (NHG): guideline Asthma in children (3rd revision). https://www.nhg.org/standaarden/volledig/nhg-standaard-astma-bij-kinderen. Published 2014

Blanken M, Bont L, Rovers M (2011) The cost-effectiveness of palivizumab in the prevention of respiratory syncytial virus bronchiolitis: a systematic review. Curr Respir Med Rev 7(3):203–212. https://doi.org/10.2174/157339811795589531 CrossRef

Blanken MO, Rovers MM, Bont L, Dutch RSV (2013) Neonatal network. Respiratory syncytial virus and recurrent wheeze. N Engl J Med 369(8):782–783. https://doi.org/10.1056/NEJMc1307429 CrossRefPubMed

Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L (2013) Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One 8(3):e59161. https://doi.org/10.1371/journal.pone.0059161 CrossRefPubMedPubMedCentral

Blanken MO, Rovers MM, Molenaar JM et al Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 368(19):1791–1799

Bos J, Rietveld E, Moll H, Steyerberg E, Luytjes W, Wilschut J, Degroot R, Postma M (2007) The use of health economics to guide drug development decisions: determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. Vaccine 25(39–40):6922–6929. https://doi.org/10.1016/j.vaccine.2007.07.006 CrossRefPubMed

10.

Brand PLP (2013) Respiratory syncytial virus and recurrent wheeze. N Engl J Med 369(8):782. https://doi.org/10.1056/NEJMc1307429#SA1 CrossRefPubMed

11.

Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford

12.

Debes AK, Gilman RH, Onyango-Makumbi C, Ruff A, Oberhelman R, Dowdy DW (2017) Cost-effectiveness of diagnostic algorithms for tuberculosis in children less than 5 years of age. Pediatr Infect Dis J 36(1):36–43. https://doi.org/10.1097/INF.0000000000001342 CrossRefPubMedPubMedCentral

13.

Eysink, PED; Blatter BM; van Gool, CH; Gommer, AM; van den Bossche, SNJ; Hoeymans N (2007) Disease burden of unfavorable work conditions in the Netherlands. http://www.rivm.nl/bibliotheek/rapporten/270012001.pdf

14.

Fekkes M, Theunissen NC, Brugman E et al (2000) Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1–5-year-old children. Qual Life Res 9(8):961–972. https://doi.org/10.1023/A:1008981603178 http://www.ncbi.nlm.nih.gov/pubmed/11284215. Accessed May 3, 2017CrossRefPubMed

15.

Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM, Losada JV, Bianchi A, Acosta PL, Talarico LB, Ferretti A, Grimaldi LA, Sancilio A, Dueñas K, Sastre G, Rodriguez A, Ferrero F, Barboza E, Gago GF, Nocito C, Flamenco E, Perez AR, Rebec B, Ferolla FM, Libster R, Karron RA, Bergel E, Polack FP (2017) Mortality due to respiratory syncytial virus. Burden and risk factors. Am J Respir Crit Care Med 195(1):96–103. https://doi.org/10.1164/rccm.201603-0658OC CrossRefPubMed

16.

GIP / Zorginstituut Nederland. No Title. https://www.gipdatabank.nl/databank.asp?tabel=01-basis&item=J06BB16&infoType=g&label=00-totaal&geg=vg

17.

Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, Lenney W, Melville S, Shaw NJ, Boorman J, Coles S, Turner J, Pang F (2004) Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 89(7):673–678. https://doi.org/10.1136/adc.2003.036129 CrossRefPubMedPubMedCentral

18.

Gregory S, Kuntz K, Sainfort F, Kharbanda A (2016) Cost-effectiveness of integrating a clinical decision rule and staged imaging protocol for diagnosis of appendicitis. Value Heal 19(1):28–35. https://doi.org/10.1016/j.jval.2015.10.007 CrossRef

19.

Hakkaart-van Roijen L, van der Linden N, Bouwmans CAM, Kanters TA, Tan S. Kostenhandleiding. Methodologie van Kostenonderzoek En Referentieprijzen Voor Economische Evaluaties in de Gezondheidszorg. (Costing manual. Methods and reference prices for economic evaluations in health care). Diemen

20.

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588–598. https://doi.org/10.1056/NEJMoa0804877 CrossRefPubMedPubMedCentral

21.

Houben ML, Bont L, Wilbrink B, Belderbos ME, Kimpen JLL, Visser GHA, Rovers MM (2011) Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 127(1):35–41. https://doi.org/10.1542/peds.2010-0581 CrossRefPubMed

22.

Isaacs D (2013) Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatr Respir Rev 14(2):128–129. https://doi.org/10.1016/j.prrv.2012.12.006 CrossRefPubMed

23.

Jansen AGSC, Sanders EAM, Hoes AW, van Loon AM, Hak E (2007) Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 30(6):1158–1166. https://doi.org/10.1183/09031936.00034407 CrossRefPubMed

24.

Jones S, Rantell K, Stevens K, Colwell B, Ratcliffe JR, Holland P, Rowan K, Parry GJ, on behalf of the United Kingdom Pediatric Intensive Care Outcome Study Group (2006) Outcome at 6 months after admission for pediatric intensive care: a report of a national study of pediatric intensive care units in the United kingdom. Pediatrics 118(5):2101–2108. https://doi.org/10.1542/peds.2006-1455 CrossRefPubMed

25.

Korsten K, Blanken MO, Nibbelke EE, Moons KGM, Bont L (2016) Dutch RSV neonatal network. Prediction model of RSV-hospitalization in late preterm infants: an update and validation study. Early Hum Dev 95:35–40. https://doi.org/10.1016/j.earlhumdev.2016.01.020 CrossRefPubMed

26.

Leader S, Jacobson P, Marcin J, Vardis R, Sorrentino M, Murray D A method for identifying the financial burden of hospitalized infants on families. Value Health 5(1):55–59. https://doi.org/10.1046/j.1524-4733.2002.51076.x

27.

Mazur NI, Martinón-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, Polack FP, Ramilo O, Sharland M, Stein R, Madhi SA, Bont L, Respiratory Syncytial Virus Network (ReSViNET) (2015) Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3(11):888–900. https://doi.org/10.1016/S2213-2600(15)00255-6 CrossRefPubMed

28.

Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, Kneyber MCJ, Wilschut JC, Hak E, Postma MJ (2012) Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine 30(31):4691–4700. https://doi.org/10.1016/j.vaccine.2012.04.072 CrossRefPubMed

29.

Miedema CJ, Kors AW, Tjon ATWE, Kimpen JL Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J 20(2):160–163

30.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EAF, Rudan I, Weber MW, Campbell H (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725):1545–1555. https://doi.org/10.1016/S0140-6736(10)60206-1 CrossRefPubMedPubMedCentral

31.

Prais D, Schonfeld T, Amir J, Israeli Respiratory Syncytial Virus Monitoring Group (2003) Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 112(3 Pt 1):548–552. https://doi.org/10.1542/peds.112.3.548 http://www.ncbi.nlm.nih.gov/pubmed/12949282. Accessed May 2, 2017CrossRefPubMed

32.

Resch B, Resch E, Müller W (2013) Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatr Respir Rev 14(2):130–136. https://doi.org/10.1016/j.prrv.2012.12.005 CrossRefPubMed

33.

Rietveld E, De Jonge HCC, Polder JJ et al (2004) Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 23(6):523–529. https://doi.org/10.1097/01.inf.0000129690.35341.8d http://www.ncbi.nlm.nih.gov/pubmed/15194833. Accessed May 2, 2017CrossRefPubMed

34.

Sampalis JS (2003) Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 143(5 Suppl):S150–S156 http://www.ncbi.nlm.nih.gov/pubmed/14615714. Accessed May 2, 2017CrossRefPubMed

35.

Shankar MB, Staples JE, Meltzer MI, Fischer M (2017) Cost effectiveness of a targeted age-based West Nile virus vaccination program. Vaccine 35(23):3143–3151. https://doi.org/10.1016/j.vaccine.2016.11.078 CrossRefPubMed

36.

Simon A, Ammann RA, Wilkesmann A, Eis-Hübinger AM, Schildgen O, Weimann E, Peltner HU, Seiffert P, Süss-Grafeo A, Groothuis JR, Liese J, Pallacks R, Müller A, DSM RSV Paed Study Group (2007) Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 166(12):1273–1283. https://doi.org/10.1007/s00431-007-0426-y CrossRefPubMed

37.

Smyth RL, Openshaw PJ (2006) Bronchiolitis. Lancet 368(9532):312–322. https://doi.org/10.1016/S0140-6736(06)69077-6 CrossRefPubMed

38.

Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, Borok G, Butylkova Y, Wegzyn C (2017) Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol 52(4):556–569. https://doi.org/10.1002/ppul.23570 CrossRefPubMed

39.

The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3 Pt 1):531–537. https://doi.org/10.1542/peds.102.3.531 http://www.ncbi.nlm.nih.gov/pubmed/9738173. Accessed May 2, 2017

40.

Utrecht Centre for Affordable Biotherapeutics. https://www.uu.nl/en/organisation/utrecht-centre-of-excellence-for-affordable-biotherapeutics/projects/biosimilar-palivizumab

41.

van Eijsden P (2015) BMJ 351:h6778. https://doi.org/10.1136/bmj.h6778 CrossRefPubMed

42.

van Giessen A, Peters J, Wilcher B, Hyde C, Moons C, de Wit A, Koffijberg E (2017) Systematic review of health economic impact evaluations of risk prediction models: stop developing, start evaluating. Value Health 20(4):718–726. https://doi.org/10.1016/j.jval.2017.01.001 CrossRefPubMed

43.

Wang D, Bayliss S, Meads C (2011) Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 15(5):iii–iiv, 1-124. https://doi.org/10.3310/hta15050 CrossRefPubMedPubMedCentral

Title: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
Authors: Maarten O. Blanken
Geert W. Frederix
Elisabeth E. Nibbelke
Hendrik Koffijberg
Elisabeth A. M. Sanders
Maroeska M. Rovers
Louis Bont
on behalf of the Dutch RSV Neonatal Network
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 1/2018
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-017-3046-1

ACC 2024 Congress

Springer Medicine

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Dynamics in prevalence of Down syndrome in children with congenital heart disease

A propensity-matched comparison of hard outcomes in children on chronic dialysis

Blood urea nitrogen to serum creatinine ratio as a prognostic factor in diarrhea-associated hemolytic uremic syndrome: a validation study

Length of stay for childbirth in Trentino (North-East of Italy): the impact of maternal characteristics and organizational features of the maternity unit on the probability of early discharge of healthy, term infants

Urinary potassium to urinary potassium plus sodium ratio can accurately identify hypovolemia in nephrotic syndrome: a provisional study

Late-onset sepsis due to urinary tract infection in very preterm neonates is not uncommon